Geron 8-K 2013
Documents found in this filing:
Date of Report (Date of Earliest Event Reported): December 9, 2013
149 COMMONWEALTH DRIVE, SUITE
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Item 7.01 Regulation FD Disclosure.
On December 9, 2013, Geron Corporation (the Company or Geron) conducted an analyst and investor meeting at which John A. Scarlett, M.D., Gerons President and Chief Executive Officer, discussed the data presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition from the investigator-sponsored trial (IST) of imetelstat in myelofibrosis being conducted at Mayo Clinic, Rochester, MN by Dr. Ayalew Tefferi. The slides accompanying Dr. Scarletts presentation, together with a slide setting forth certain cautionary language intended to qualify the forward-looking statements included in the presentation and the question and answer session, are furnished as Exhibit 99.1 to this Current Report and are incorporated herein by reference. The slides are also available in the Investor Relations section of Gerons website, located at www.geron.com.
The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act). The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.